News Study finds weight returns more quickly in GLP-1 users People who use drugs like GLP-1 agonists to lose weight regain it more quickly than those who use a conventional approach of diet and exercise.
News Novo Nordisk launches Wegovy pill at $149 a month Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.
News CMS aims for broader GLP-1 access via federal programmes CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
News Novo Nordisk gets FDA okay for Wegovy pill The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.
News Lilly points to long-lasting weight loss with orforglipron Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
News Novo Nordisk files Wegovy product that claimed rapid voucher Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.